Silence Therapeutics Files 6-K, Incorporates Exhibits
Ticker: SLNCF · Form: 6-K · Filed: Jun 20, 2024 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 6-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, registration
TL;DR
Silence Therapeutics filed a routine 6-K, incorporating exhibits into existing S-8 filings. No major news.
AI Summary
Silence Therapeutics plc filed a Form 6-K on June 20, 2024, incorporating Exhibit 99.1 by reference into its existing Form S-8 registration statements (File Nos. 333-248682 and 333-273576). This filing is routine for a foreign private issuer and does not appear to contain new material financial or operational information.
Why It Matters
This filing is a standard procedural update for Silence Therapeutics, indicating ongoing compliance with SEC reporting requirements for its listed securities.
Risk Assessment
Risk Level: low — The filing is a standard procedural document and does not disclose new material information that would typically impact risk.
Key Players & Entities
- Silence Therapeutics plc (company) — Filer of the Form 6-K
- 0001193125-24-164042 (filing_id) — Accession Number for the filing
- 20240620 (date) — Filing date and period of report
- Form S-8 (document) — Registration statements into which exhibits are incorporated
- 333-248682 (filing_id) — File number for a Form S-8 registration statement
- 333-273576 (filing_id) — File number for a Form S-8 registration statement
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report information that Silence Therapeutics plc is required to disclose to any or all of its security holders, specifically by incorporating Exhibit 99.1 into its existing Form S-8 registration statements.
When was this Form 6-K filed?
This Form 6-K was filed on June 20, 2024.
Which registration statements are being updated by this filing?
The filing incorporates Exhibit 99.1 into the registration statements on Form S-8 with File Numbers 333-248682 and 333-273576.
What is the company's principal executive office address?
The company's principal executive offices are located at 72 Hammersmith Road, London W14 8TH, United Kingdom.
Is Silence Therapeutics plc required to file annual reports on Form 20-F?
Yes, Silence Therapeutics plc indicates it files annual reports under cover of Form 20-F.
Filing Stats: 302 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2024-06-20 08:41:27
Filing Documents
- d779524d6k.htm (6-K) — 10KB
- d779524dex991.htm (EX-99.1) — 10KB
- g779524g0620021901435.jpg (GRAPHIC) — 3KB
- 0001193125-24-164042.txt ( ) — 26KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-39487 Silence Therapeutics plc (Exact Name of Registrant as Specified in Its Charter) 72 Hammersmith Road London W14 8TH United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INCORPORATION BY REFERENCE Exhibit 99.1 to this Report on Form 6-K (the Report) shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Nos. 333-248682 and 333-273576) and the registration statements on Form F-3 (File Nos. 333-279185, 333-260265 and 333-279185) of Silence Therapeutics plc (the Company) and to be a part thereof from the date on which this Report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K Filed as Exhibit 99.1 to this Report on Form 6-K is a press release of Silence Therapeutics plc, dated June 20, 2024. EXHIBIT INDEX Exhibit No. Description 99.1 Press release, dated June 20, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SILENCE THERAPEUTICS PLC Date: June 20, 2024 By: /s/ Craig Tooman Craig Tooman President and Chief Executive Officer